Previous studies have indicated that arachidonic acid (AA) and its metabolite 11,12-EET but not other regioisomers of EETs inhibit ENaC activity in the collecting duct. The goal of this study was to investigate the endogenous metabolism of AA in cultured mpkCCD c14 principal cells and the effects of these metabolites on ENaC activity. Liquid chromatography/mass spectrometry analysis of the mpkCCD c14 cells indicated that these cells produce prostaglandins, 8,9-EET, 11,12-EET, 14,15-EET, 5-HETE, 12/8-HETE, and 15-HETE, but not 20-HETE. Single-channel patch-clamp experiments revealed that 8,9-EET, 14,15-EET, and 11,12-EET all decrease ENaC activity. Neither 5-, 12-, nor 15-HETE had any effect on ENaC activity. Diclofenac and ibuprofen, inhibitors of cyclooxygenase, decreased transepithelial Na ϩ transport in the mpkCCDc14 cells. Inhibition of cytochrome P-450 (CYP450) with MS-PPOH activated ENaC-mediated sodium transport when cells were pretreated with AA and diclofenac. Coexpression of CYP2C8, but not CYP4A10, with ENaC in Chinese hamster ovary cells significantly decreased ENaC activity in whole-cell experiments, whereas 11,12-EET mimicked this effect. Thus both endogenously formed EETs and their exogenous application decrease ENaC activity. Downregulation of ENaC activity by overexpression of CYP2C8 was PKA dependent and was prevented by myristoylated PKI treatment. Biotinylation experiments and single-channel analysis revealed that long-term treatment with 11,12-EET and overexpression of CYP2C8 decreased the number of channels in the membrane. In contrast, the acute inhibitory effects are mediated by a decrease in the open probability of the ENaC. We conclude that 11,12-EET, 8,9-EET, and 14,15-EET are endogenously formed eicosanoids that modulate ENaC activity in the collecting duct. aldosterone; eicosanoids; 11,12-EET; 8,9-EET; 14,15-EET; 20-HETE; prostaglandins THE EPITHELIAL SODIUM CHANNEL (ENaC) is thought to represent the rate-limiting step for sodium absorption in the renal collecting duct. Consequently, ENaC is a central effector that impacts blood volume and systemic arterial pressure regulation. ENaC is localized to the luminal plasma membrane of epithelial cells and is involved in Na ϩ homeostasis. Multiple factors regulate the renal handling of sodium, including the renin-angiotensin-aldosterone system, nitric oxide, arachidonic acid (AA), and its metabolites. AA is primarily metabolized by cytochrome P-450 enzymes to 19-and 20-HETE and EETs (5,6-, 8,9-, 11,12-, and 14,15-EET) in the renal cortex, and these compounds have been shown to play critical roles in the regulation of renal tubular and vascular function (34). Cytochrome P-450 members of the CYP2C and CYP4A families are the predominant epoxygenases and -hydroxylase enzymes expressed in the kidney (5). The cyp4A isoform has been reported to be expressed in the cortical collecting ducts (CCD) (15). Knockdown of the Cyp4a10 gene in mice produces a salt-sensitive form of hypertension that is associated with alterations in the activity of ENaC (28...